Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis
| Status: | Enrolling by invitation |
|---|---|
| Conditions: | Hematology |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | 18 - 100 |
| Updated: | 8/15/2018 |
| Start Date: | March 13, 2017 |
| End Date: | December 2020 |
The primary aim of this study will be to examine the diagnostic utility of 18-F Florbetapir
PET/MR (Positron Emission Tomography/Magnetic Resonance) in imaging patients with
pathologically-confirmed systemic amyloidosis involving the peripheral nerves and compare
these results to non-amyloid diseased controls.
PET/MR (Positron Emission Tomography/Magnetic Resonance) in imaging patients with
pathologically-confirmed systemic amyloidosis involving the peripheral nerves and compare
these results to non-amyloid diseased controls.
Patients with pathologically proven amyloidosis involving the peripheral nervous system will
undergo 18-F Florbetapir PET/MR on a GE (General Electric Healthcare) SIGNA PET/MR scanner. A
control arm comprised of patients with pathologically-confirmed non-amyloid causes of
peripheral neuropathy will also undergo 18-F Florbetapir PET/MR scanning. all images will be
reviewed for peripheral nerve uptake.
undergo 18-F Florbetapir PET/MR on a GE (General Electric Healthcare) SIGNA PET/MR scanner. A
control arm comprised of patients with pathologically-confirmed non-amyloid causes of
peripheral neuropathy will also undergo 18-F Florbetapir PET/MR scanning. all images will be
reviewed for peripheral nerve uptake.
Inclusion Criteria:
- Adults: 18-100
- Pathologically-confirmed peripheral nerve amyloidosis or pathologically-confirmed
non-amyloid causes of peripheral neuropathy
Exclusion Criteria:
- Metallic devices that are not MR safe (cardiac pacers, stents, aneurysm coils, etc.)
- Claustrophobia
- BMI over 38
We found this trial at
1
site
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
Click here to add this to my saved trials
